This pharmaceutical company transformed net losses into astonishing net profits!

Fourth quarter and year ended March 31, 2023 results were reported by Lupin Ltd. 

Quarterly Performance: 

Comparing the fourth quarter of 2023 to the same quarter the year prior, the company reported a net profit of Rs 242.39 crore on a consolidated basis as opposed to a net loss of Rs 511.73 crore. In Q4FY23, the company's total revenue climbed by 14.59% to Rs 4,467.35 crore from Rs 3,898.71 crore in the similar quarter the year prior. 

The company declared a net profit of Rs 447.69 crore for the fiscal year that ended on March 31, 2023, as opposed to a net loss of Rs 1,509.36 crore the year before. When compared to the year ended March 31, 2022, the company's total revenue increased by 1.01% to Rs 16,715.02 crore from Rs 16,541.17 crore during the year under review. 

Share Price Movement: 

In the last trading session script closed at Rs 745.80 and today it opened at Rs 752. Currently, it is trading at Rs 742.10. Till now the scrip has touched a high and low of Rs 753 and Rs 734.25, respectively. So far 68,086 shares were traded on the counter at BSE. 

It has a 52-week high and low of Rs 788.90 and 583.05, respectively. It is BSE group 'A' stock with a face value of Rs 2 and a market cap of Rs 33,751.54 crore. 

Company Profile: 

Lupin manufactures pharmaceuticals as a part of its business. It developed into one of the world's fastest-growing generic pharmaceutical enterprises. Lupin is regarded as one of the biggest producers of anti-tuberculosis medications worldwide. The company holds a large market position in a number of therapeutic categories, including those for the cardiovascular system, diabetes, asthma, digestive tract, central nervous system, and non-steroidal anti-inflammatory drugs (NSAIDs). Additionally, the business has been proud to hold onto its global leadership positions in other therapy areas including anti-TB and cephalosporin over the years.